ArticleArchives of osteoporosis2025

A comprehensive update on the cost-effectiveness of 10-year denosumab vs alendronate in postmenopausal women with osteoporosis in the United States.

Eric Yeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.